(a)
(b)
(c)
Figure 1: The clinical effects of the combination therapy with BSF plus ETV in CHB patients. Serum HBV DNA, HBsAg, and HBeAg levels were evaluated before and after treatment. (a) HBV DNA-negative rates in HBeAg(−) patients were higher than those in HBeAg(+) patients in both T1-Group and C1-Group. (b) HBeAg-negative rate in T2-Group was higher than that in C2-Group, although there was no significant difference. (c) The rate of HBsAg decline ≥ 20% in HBeAg(+) patients in T2-Group was higher than that in HBeAg(+) patients in C2-Group.